Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd

Link copied
Case Copied 83 min read

FEDERAL COURT OF AUSTRALIA

Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd [2015] FCA 113

Citation: Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd [2015] FCA 113
Parties: AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v PFIZER AUSTRALIA PTY LTD (ACN 008 422 348)
File number: NSD 146 of 2014
Judge: FLICK J
Date of judgment: 25 February 2015
Catchwords:

TRADE PRACTICES – abuse of market power – definition of market – substantial degree of power – taking advantage of power – purpose

TRADE PRACTICES – exclusive dealing – on condition – purpose

PATENTS – exclusive rights of patentee - right to exploit – right to exclude others - an implied licence to sell – whether a condition falling within trade practices exception to s 47

EVIDENCE – the rule in Browne v Dunn – a rule of procedural fairness – privilege against self-incrimination

Legislation: Competition and Consumer Act 2010 (Cth) ss 4E, 4F, 4G, 46, 47, 51, 76
Copyright Act 1968 (Cth)
Evidence Act 1995 (Cth) s 128
National Health Act1953 (Cth) Pt VII
Patents Act 1990 (Cth) ss 13, 117, Sch 1
Trade Practices Act 1974 (Cth) ss 45, 45D, 46, 47, 51, 51AC
Trade Practices Amendment Act 1977 (Cth)
Trade Practices (Misuse of Trans-Tasman Market Power) Act 1990 (Cth)

Cases cited:

ASX Operations Pty Ltd v Pont Data Australia Pty Ltd (No 1) (1990) 27 FCR 460
Australian Competition and Consumer Commission v Air New Zealand Limited [2014] FCA 1157
Australian Competition and Consumer Commission v Australian Safeway Stores Pty Ltd [2003] FCAFC 149, (2003) 129 FCR 339
Australian Competition and Consumer Commission v Baxter Healthcare Pty Ltd (No 2) [2008] FCAFC 141, (2008) 170 FCR 16
Australian Competition and Consumer Commission v Boral Ltd [1999] FCA 1318, (1999) 166 ALR 410
Australian Competition and Consumer Commission v Australia and New Zealand Banking Group Limited [2013] FCA 1206
Australian Competition and Consumer Commission v Cement Australia Pty Ltd [2013] FCA 909, (2013) 310 ALR 165
Australian Competition and Consumer Commission v Flight Centre Ltd [2013] FCA 1313, (2013) 307 ALR 209
Australian Competition and Consumer Commission v Liquorland (Australia) Pty Ltd [2006] FCA 826, (2006) ATPR 42,123
Australian Competition and Consumer Commission v Metcash Trading Ltd [2011] FCAFC 151, (2011) 198 FCR 297
Australian Competition and Consumer Commission v Qantas Airways Ltd [2008] FCA 1976; (2008) 253 ALR 89
Australian Competition and Consumer Commission v Telstra Corporation Ltd [2010] FCA 790, (2010) 188 FCR 238
Australian Competition and Consumer Commission v Titan Marketing Pty Ltd [2014] FCA 913
Australian Gas Light Company v Australian Competition and Consumer Commission [2003] FCA 1525, (2003) 137 FCR 317
Australian Wool Innovation Ltd v Newkirk [2005] FCA 290, (2005) ATPR 42-053
Baxter Healthcare Pty Limited v ACCC [2009] HCATrans 20
Boral Besser Masonry Limited v Australian Competition and Consumer Commission [2003] HCA 5, (2003) 215 CLR 374
Browne v Dunn (1893) 6 R 67
Damorgold…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Australian Competition and Consumer Commission v Pfizer Aust... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] FCA 113
Decision Date

CaseChat Overview and Summary

The Australian Competition and Consumer Commission brought an action against Pfizer Australia Pty Ltd in relation to its conduct in the market for the pharmaceutical product atorvastatin. The Commission alleged that Pfizer abused its market power by engaging in exclusive dealing practices that were anti-competitive. The Federal Court was tasked with determining whether Pfizer's actions amounted to an abuse of market power under the Competition and Consumer Act 2010.

The court was required to consider several legal issues, including the definition of market power and whether Pfizer held substantial market power in the atorvastatin market. It also needed to examine whether Pfizer's conduct amounted to taking advantage of its market power and whether the purpose behind its actions was to eliminate or harm competition. Additionally, the court had to determine whether the exclusive dealing arrangements between Pfizer and the pharmacies constituted a breach of the Act.

The court concluded that Pfizer did not hold substantial market power in the atorvastatin market, and therefore, the issue of abuse of market power did not arise. The court found that Pfizer's decision to enter the generic market and its implementation of the Direct-to-Pharmacy Model and the rebate scheme were reasonable business decisions aimed at competing in the market. The court held that the exclusive dealing arrangements did not amount to an abuse of market power as they were necessary to compete with established generic manufacturers and pharmacies. The court also rejected the Commission's argument that the rebates were an unlawful condition falling within the trade practices exception to section 47 of the Act.

ORDERS:
1. The Amended Originating Application filed by the Australian Competition and Consumer Commission is dismissed.
2. The Applicant is to pay the costs of the Respondent.

Orders

Orders of the court

1. The Amended Originating Application filed by the Australian Competition and Consumer Commission is dismissed.

2. The Applicant is to pay the costs of the Respondent.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Had it been necessary to resolve this argument, it would have been rejected for either of two reasons, namely:·the sale of the atorvastatin by Pfizer to the pharmacies would not have been held to involve the granting of any “licence”; and, perhaps more relevantly:·the “condition” otherwise contained within any such licence would not have been held to constitute a “condition” to which s 51(3) applied. Section 51(3), it has been said, “determines the scope of restrictions the patentee may properly impose on the use of the patent. Conditions which seek to gain advantages collateral to the patent are not covered by s 51(3)”: Transfield Proprietary Limited v Arlo International Limited (1980) 144 CLR 83 at 103 per Mason J. The relevant “conditions”, it would have been concluded were “conditions” which sought to gain “advantages collateral to the patent…”.CONCLUSIONS The central facts relevant to the resolution of the present dispute, once stripped from the necessary but possibly distracting detail, are within a narrow compass. The situation confronting Pfizer in Australia as at 2009 was that a number of its patents over its pharmaceutical products were coming to an end. Its exclusive rights to distribute those products would therefore be lost. Amongst those patents was the patent over atorvastatin, a pharmaceutical product which had long contributed immensely to the revenues of Pfizer. Its “brand” product, Lipitor, would continue to be available. But it would inevitably confront competition from the existing generic manufacturers, and possibly new generic manufacturers, who would wish to establish their own share of a lucrative source of income. Pfizer had decisions to make. One option was to simply continue to manufacture and sell its “branded” product. Another option was to manufacture and market its own generic atorvastatin. That was the path it decided to go down. But, in so deciding, it inevitably had to confront the reality that there were well-established arrangements between the generic manufacturers and many of the pharmacies. Those arrangements were such that the pharmacies were likely to sell the generic product supplied by the manufacturer with which it had an arrangement. In entering the generic market, Pfizer was entering a market in respect to which it had relatively no prior experience. The strategy that it developed was to depart from its traditional method of distributing its products to pharmacies through wholesalers. To confront the challenges faced by existing generic manufacturers and many of the pharmacies, Pfizer decided to implement what it described as a Direct-to-Pharmacy Model whereby it would sell and deliver its products direct to the pharmacies. It also developed a scheme to give a “rebate” on its branded product which could be “unlocked” by pharmacies accepting one or other of the offers it made. But those offers were dependent upon supplying substantial quantities of its generic atorvastatin. Discounts on the sales of Lipitor were “bundled” with Pfizer’s generic product.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.